If MTAP activity in serum were high enough to convert administered MTA (or another MTAP substrate) to significant levels of adenine, this might indiscriminately protect not just MTAP-positive host cells, but MTAP-negative tumor cells as well. This evidence concerns the gene MTAP and neoplasm.